Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Acchiardo

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Drug Intelligence & Clinical Pharmacy|December 1, 1986
Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal diseaseV A Skoutakis, S R Acchiardo, C A Carter, et al.
Transplantation|February 27, 1996
Clinical observations of metabolic changes occurring in renal transplant recipients receiving ketoconazoleL W Moore, R R Alloway, S R Acchiardo, et al.
Journal of Clinical Pharmacology|November 1, 1985
The comparative bioavailability of liquid, wax-matrix, and microencapsulated preparations of potassium chlorideV A Skoutakis, S R Acchiardo, N J Wojciechowski, et al.
Circulation Research|June 1, 1975
Malignant hypertension due to musculo-mucoid intimal hyperplasia of intrarenal arteries. Absence of renal fibrinoid necrosisJ A Pitcock, J G Johnson, L Share, et al.
Free Radical Research|January 29, 2002
An enzyme hydrolyzing methylated inhibitors of nitric oxide synthase is present in circulating human red blood cellsE S Kang, T B Cates, D N Harper, et al.
The American Journal of the Medical Sciences|January 19, 1999
Hemodialysis hypotension: interaction of inhibitors, iNOS, and the interdialytic periodE S Kang, M T Tevlin, Y B Wang, et al.
AJR. American Journal of Roentgenology|February 1, 1984
Radiographic manifestations of aluminum-induced bone diseaseJ I Sebes, M L Pinstein, J D Massie, et al.
Clinical Science and Molecular Medicine. Supplement|June 11, 1975
Treatment of patients with severe hypertension by inhibition of angiotensin-converting enzymeJ G Johnson, W D Black, R A Vukovich, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 8, 2000
Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidismJ M Frazão, L Elangovan, H M Maung, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 3, 2001
Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparisonH M Maung, L Elangovan, J M Frazão, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Drug Intelligence & Clinical Pharmacy|December 1, 1986
Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal diseaseV A Skoutakis, S R Acchiardo, C A Carter, et al.
Transplantation|February 27, 1996
Clinical observations of metabolic changes occurring in renal transplant recipients receiving ketoconazoleL W Moore, R R Alloway, S R Acchiardo, et al.
Journal of Clinical Pharmacology|November 1, 1985
The comparative bioavailability of liquid, wax-matrix, and microencapsulated preparations of potassium chlorideV A Skoutakis, S R Acchiardo, N J Wojciechowski, et al.
Circulation Research|June 1, 1975
Malignant hypertension due to musculo-mucoid intimal hyperplasia of intrarenal arteries. Absence of renal fibrinoid necrosisJ A Pitcock, J G Johnson, L Share, et al.
Free Radical Research|January 29, 2002
An enzyme hydrolyzing methylated inhibitors of nitric oxide synthase is present in circulating human red blood cellsE S Kang, T B Cates, D N Harper, et al.
The American Journal of the Medical Sciences|January 19, 1999
Hemodialysis hypotension: interaction of inhibitors, iNOS, and the interdialytic periodE S Kang, M T Tevlin, Y B Wang, et al.
AJR. American Journal of Roentgenology|February 1, 1984
Radiographic manifestations of aluminum-induced bone diseaseJ I Sebes, M L Pinstein, J D Massie, et al.
Clinical Science and Molecular Medicine. Supplement|June 11, 1975
Treatment of patients with severe hypertension by inhibition of angiotensin-converting enzymeJ G Johnson, W D Black, R A Vukovich, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 8, 2000
Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidismJ M Frazão, L Elangovan, H M Maung, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 3, 2001
Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparisonH M Maung, L Elangovan, J M Frazão, et al.
Pageof 5